PropFirmUs
E

Equity Edge

4.7 (12 reviews)
Trust Score 76%

United States

Equity Edge is a proprietary trading firm offering funded accounts up to $300,000 with a 80% profit split.

Funding

$25,000 - $300,000

Profit Split

80%

Max Allocation

$1,500,000

Payout Frequency

Monthly

MT4
MT5
cTrader
ONE STEP

Brokers

iFOREX

Funding Programs

Standard Evaluation

Account Size
$150,000
Price
$600
Profit Split
80%
Max Drawdown
6%
Daily Drawdown
5%
Profit Target
8%

Pros & Cons

Pros

  • +80% profit split on funded accounts
  • +Monthly payouts
  • +Supports MT4 and MT5 and cTrader

Cons

  • Evaluation phase required before receiving a funded account
  • Larger accounts carry stricter drawdown rules
  • Verify current rules and pricing directly with the firm before purchasing

FAQ

What platforms does Equity Edge support?

Equity Edge supports MT4, MT5, cTrader.

Reviews

Jul 6, 2026

Highly recommend

Best prop firm I've used so far, smooth payout process.

Alex Trader

Jul 6, 2026

Solid rules

Drawdown rules are fair, support could be faster.

Alex Trader

Jul 6, 2026

Great experience

Got funded in two weeks and payouts were on time.

Alex Trader

Jul 6, 2026

Highly recommend

Best prop firm I've used so far, smooth payout process.

Alex Trader

Jul 6, 2026

Solid rules

Drawdown rules are fair, support could be faster.

Alex Trader

Jul 6, 2026

Great experience

Got funded in two weeks and payouts were on time.

Alex Trader

Jul 5, 2026

Highly recommend

Best prop firm I've used so far, smooth payout process.

Alex Trader

Jul 5, 2026

Solid rules

Drawdown rules are fair, support could be faster.

Alex Trader

Jul 5, 2026

Great experience

Got funded in two weeks and payouts were on time.

Alex Trader

Jul 5, 2026

Highly recommend

Best prop firm I've used so far, smooth payout process.

Alex Trader

Jul 5, 2026

Solid rules

Drawdown rules are fair, support could be faster.

Alex Trader

Jul 5, 2026

Great experience

Got funded in two weeks and payouts were on time.

Alex Trader

Log in to leave a review.